Cwm, LLC Ocular Therapeutix, Inc Transaction History

Cwm, LLC

$33.3 Billion
Q3 2025

A detailed history of Cwm, LLC transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Cwm, LLC holds 1,317 shares of OCUL stock, worth $15,408. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,317

Previous 707 86.28%

Holding current value

$15,408

Previous $7,000 114.29%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 15, 2025	BUY	$9.09 - $13.6 $5,544 - $8,296	610 Added 86.28%	1,317 $15,000
Q2 2025 Jul 25, 2025	BUY	$6.02 - $9.46 $2,913 - $4,578	484 Added 217.04%	707 $7,000
Q1 2025 May 01, 2025	SELL	$5.93 - $9.08 $847 - $1,298	-143 Reduced 39.07%	223 $2,000
Q4 2024 Feb 04, 2025	BUY	$8.33 - $11.47 $1,399 - $1,926	168 Added 84.85%	366 $3,000
Q3 2024 Oct 08, 2024	BUY	$6.45 - $9.23 $1,212 - $1,735	188 Added 1880.0%	198 $2,000
Q2 2024 Jul 09, 2024	BUY	$4.2 - $8.69 $42 - $86	10 New	10 $0
Q1 2020 Sep 15, 2021	BUY	$3.95 - $7.4 $7,900 - $14,800	2,000 New	2,000 $28,000
Q1 2020 Apr 28, 2020	SELL	$3.95 - $7.4 $7,900 - $14,800	-2,000 Closed	0 $0
Q4 2019 Sep 14, 2021	SELL	$2.57 - $4.73 $2,570 - $4,730	-1,000 Reduced 33.33%	2,000 $28,000
Q4 2019 Jan 27, 2020	BUY	$2.57 - $4.73 $2,570 - $4,730	1,000 Added 50.0%	3,000 $12,000
Q3 2019 Sep 14, 2021	BUY	$3.04 - $5.32 $6,080 - $10,640	2,000 New	2,000 $28,000
Q3 2019 Oct 22, 2019	SELL	$3.04 - $5.32 $6,080 - $10,640	-2,000 Closed	0 $0
Q2 2019 Sep 14, 2021	BUY	$2.46 - $4.52 $4,920 - $9,040	2,000 New	2,000 $28,000
Q2 2019 Jul 31, 2019	SELL	$2.46 - $4.52 $4,920 - $9,040	-2,000 Closed	0 $0
Q1 2019 Sep 02, 2021	BUY	$3.51 - $4.77 $7,020 - $9,540	2,000 New	2,000 $0

Others Institutions Holding OCUL

# of Institutions

206

Shares Held

137M

Call Options Held

743K

Put Options Held

321K

View Full List

About OCULAR THERAPEUTIX, INC

Ticker OCUL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,966,896
Market Cap $901M
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...

More about OCUL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account